Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. Oktober 2025 09:27 ET | Quelle: Spherix Global Insights

Evolving Treatment Landscape for Chronic Spontaneous Urticaria Highlights Significant Unmet Needs and Expanding Opportunities for Therapeutic Innovation

EXTON, PA, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Chronic spontaneous urticaria (CSU), marked by unpredictable and often debilitating flare patterns, continues to impose a significant burden on patients...
06. März 2024 09:57 ET | Quelle: Latitude Food Allergy Care

Latitude Food Allergy Care Announces the Opening of its New San Francisco Clinic; Pacific Heights Clinic is the First-of-its-Kind and Only Clinic in San Francisco Specifically Dedicated to Food Allergy Patients

San Francisco, CA, March 06, 2024 (GLOBE NEWSWIRE) -- Latitude Food Allergy Care, the leading network of clinics providing life-changing testing and treatment, including oral immunotherapy (OIT) and...
16. Februar 2024 11:24 ET | Quelle: F. Hoffmann-La Roche Ltd

FDA approves Xolair as first and only medicine for children and adults with one or more food allergies

Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate...
14. Dezember 2023 05:48 ET | Quelle: Research and Markets

Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review 2023

Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides...